Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
The Effect of Three-Monthly Albendazole Treatment on Malarial Parasitemia and Allergy: A Household-Based Cluster-Randomized, Double-Blind, Placebo-Controlled Trial
PLoS ONE, Volume 8, No. 3, Article e57899, Year 2013
Notification
URL copied to clipboard!
Description
Background: Helminth infections are proposed to have immunomodulatory activities affecting health outcomes either detrimentally or beneficially. We evaluated the effects of albendazole treatment, every three months for 21 months, on STH, malarial parasitemia and allergy. Methods and Findings: A household-based cluster-randomized, double-blind, placebo-controlled trial was conducted in an area in Indonesia endemic for STH. Using computer-aided block randomization, 481 households (2022 subjects) and 473 households (1982 subjects) were assigned to receive placebo and albendazole, respectively, every three months. The treatment code was concealed from trial investigators and participants. Malarial parasitemia and malaria-like symptoms were assessed in participants older than four years of age while skin prick test (SPT) to allergens as well as reported symptoms of allergy in children aged 5-15 years. The general impact of treatment on STH prevalence and body mass index (BMI) was evaluated. Primary outcomes were prevalence of malarial parasitemia and SPT to any allergen. Analysis was by intention to treat. At 9 and 21 months post-treatment 80.8% and 80.1% of the study subjects were retained, respectively. The intensive treatment regiment resulted in a reduction in the prevalence of STH by 48% in albendazole and 9% in placebo group. Albendazole treatment led to a transient increase in malarial parasitemia at 6 months post treatment (OR 4.16(1.35-12.80)) and no statistically significant increase in SPT reactivity (OR 1.18(0.74-1.86) at 9 months or 1.37 (0.93-2.01) 21 months). No effect of anthelminthic treatment was found on BMI, reported malaria-like- and allergy symptoms. No adverse effects were reported. Conclusions: The study indicates that intensive community treatment of 3 monthly albendazole administration for 21 months over two years leads to a reduction in STH. This degree of reduction appears safe without any increased risk of malaria or allergies. Trial Registration: Controlled-Trials.com ISRCTN83830814. © 2013 Wiria et al.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC3602425/bin/pone.0057899.s001.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC3602425/bin/pone.0057899.s002.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC3602425/bin/pone.0057899.s003.doc
Authors & Co-Authors
Wiria, Aprilianto Eddy
Indonesia, Depok
Universitas Indonesia
Netherlands, Leiden
Leids Universitair Medisch Centrum
Hamid, Firdaus
Netherlands, Leiden
Leids Universitair Medisch Centrum
Indonesia, Makassar
Hasanuddin University
Wammes, Linda Judith
Netherlands, Leiden
Leids Universitair Medisch Centrum
Kaisar, Maria M.M.
Indonesia, Depok
Universitas Indonesia
Netherlands, Leiden
Leids Universitair Medisch Centrum
May, Linda
Netherlands, Leiden
Leids Universitair Medisch Centrum
Prasetyani, Margaretta A.
Indonesia, Depok
Universitas Indonesia
Netherlands, Leiden
Leids Universitair Medisch Centrum
Wahyuni, Sitti
Indonesia, Makassar
Hasanuddin University
Djuardi, Yenny
Indonesia, Depok
Universitas Indonesia
Netherlands, Leiden
Leids Universitair Medisch Centrum
Ariawan, Iwan
Indonesia, Depok
Universitas Indonesia
Wibowo, Heri
Indonesia, Depok
Universitas Indonesia
Lell, Bertrand
Gabon, Lambarene
Unité de Recherche Médicale, Albert Schweitzer Hospital
Germany, Tubingen
Eberhard Karls Universität Tübingen
Sauerwein, Robert W.
Netherlands, Nijmegen
Radboud University Medical Center
Brice, Gary T.
Indonesia, Jakarta
U.s. Naval Medical Research Unit No. 2, Jakarta
Sutanto, Inge
Indonesia, Depok
Universitas Indonesia
van Lieshout, Lisette
Netherlands, Leiden
Leids Universitair Medisch Centrum
De Craen, Anton J.N.
Netherlands, Leiden
Leids Universitair Medisch Centrum
van Ree, Ronald
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Verweij, Jaco J.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Netherlands, Tilburg
St. Elisabeth Ziekenhuis
Tsonaka, Roula
Netherlands, Leiden
Leids Universitair Medisch Centrum
Houwing-Duistermaat, Jeanine J.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Luty, A. J.F.
Netherlands, Nijmegen
Radboud University Medical Center
France, Marseille
Ird Institut de Recherche Pour le Developpement
Sartono, Erliyani
Netherlands, Leiden
Leids Universitair Medisch Centrum
Supali, Taniawati
Indonesia, Depok
Universitas Indonesia
Yazdanbakhsh, Maria M.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Statistics
Citations: 61
Authors: 24
Affiliations: 10
Identifiers
Doi:
10.1371/journal.pone.0057899
e-ISSN:
19326203
Research Areas
Disability
Infectious Diseases
Maternal And Child Health
Study Design
Randomised Control Trial
Cross Sectional Study